Trial Profile
A phase I study of MAT2501 for the treatment of for the treatment of non-tuberculous mycobacteria (NTM) infections
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2017
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Gram-negative infections; Mycobacterial infections; Nontuberculous mycobacterium infections
- Focus Adverse reactions; Pharmacokinetics
- 27 Mar 2017 Topline results published in a Matinas BioPharma media release.
- 27 Mar 2017 Status changed from recruiting to completed, according to a Matinas BioPharma media release.
- 08 Mar 2017 According to a Matinas BioPharma media release, top line results from this trial will be reported in the coming weeks.